Standard Drug Discovery and Development

$1 to $2 billion

Cost of a new drug development

10 to 15 years

To develop a new drug

1:10k

Success rate

We can reduce those numbers to

$250k – $50M

Cost of a new drug development

4 to 5 years

To develop a new drug

3:10

Success rate

OUR APPROACH

Artificial Intelligence

Propietary Databases of Chemical Structures

Scientific Expertise

Our Directions of Work

Proprietary pipeline

Proprietary pipeline

PARTNERSHIP

Our performance indicators

12%

of our performed projects have
reached Clinical Phase 2

29%

of our projects have a positive
in vitro lead

We cooperate with

SOM Biotech in the media

LATEST NEWS

A pioneering real AI drug discovery technology
European Biotechnology: “A pioneering real AI drug discovery technology”
November 26, 2020

European Biotechnology Life Science and Industry Magazine published the article “A pioneering real AI drug discovery technology” describing the approach of SOM Biotech. The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to ...

La Vanguardia press release: “The future of biotechnology: lower-cost treatments in a short period of time”
November 26, 2020

La Vanguardia published a press release: “The future of biotechnology: lower-cost treatments in a short period of time”. You can find a short overview of the press release below. SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more ...

SOM Biotech keynote speaker at the Drug Discovery Innovation Programme Virtual Event 2020
November 16, 2020

SOM Biotech announces its participation at the Drug Discovery Innovation Programme event 2020, being held virtually on November 17th. The conference will be chaired by Kevin McAllister, PhD, MBA Chief Scientific Officer. As a keynote speaker, Maria Zimina, PhD. MBA, Business Development Manager, will present “AI Evolutionary Algorithms for the ...

SOM Biotech presents its drug candidate for the Chorea in Huntington Disease at the XIX Pharma – Biotech Cooperation conference
November 10, 2020

SOM Biotech presents its drug candidate SOM3355 for the Chorea in Huntington Disease at the XIX Pharma-Biotech Cooperation conference, November 12th 2020. The conference, an initiative of Farmaindustria – the National Trade Association of the Spanish based pharmaceutical industry –  allows companies previously selected for their contribution to innovation, to present ...

SOM Biotech at BIO-Europe 2020 Digital Convention
October 20, 2020

SOM Biotech will attend the “BIO-Europe 2020” convention on October 26th – 29th, which will take place digitally due to the pandemic situation. Raúl Insa, CEO of SOM Biotech: “BIO-Europe 2020 is one of the most relevant partnering events for the life science sector. We look forward to meeting with ...

SOM Biotech announces poster presentation on the repurposing of Eravacycline for the treatment of SARS-CoV-2
October 19, 2020

SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020. The poster is entitled “Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections”. It outlines pre-clinical data demonstrating that Eravacycline ...

SOM Biotech has attended the virtual workshop on the World Duchenne Awareness Day 2020
September 14, 2020

SOM Biotech has attended the virtual V Workshop “Duchenne and the Brain” organized by the Duchenne Parent Project Spain on September 7th, on the occasion of the World Duchenne Awareness Day 2020. Gal·la Pericot, R&D Manager of SOM Biotech: “The Duchenne Parent Project Spain is a valuable initiative to encourage collaboration among R&D ...

SOM Biotech is awarded a grant from CDTI to start clinical trials with a drug inhibitor of SARS- COV-2 replication
August 6, 2020

SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment ...